Intra-Pancreatic Insulin Nourishes Cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?
- PMID: 32468825
- DOI: 10.1142/S0192415X20500482
Intra-Pancreatic Insulin Nourishes Cancer Cells: Do Insulin-Receptor Antagonists such as PGG and EGCG Play a Role?
Abstract
Harboring insulin-producing cells, the pancreas has more interstitial insulin than any other organ. In vitro, insulin activates both insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) to stimulate pancreatic cancer cells. Whether intra-pancreatic insulin nourishes pancreatic cancer cells in vivo remains uncertain. In the present studies, we transplanted human pancreatic cancer cells orthotopically in euglycemic athymic mice whose intra-pancreatic insulin was intact or was decreased following pretreatment with streptozotocin (STZ). In the next eight weeks, the tumor carriers were treated with one of the IR/IGF1R antagonists penta-O-galloyl-[Formula: see text]-D-glucose (PGG) and epigallocatechin gallate (EGCG) or treated with vehicle. When pancreatic tumors were examined, their fraction occupied with living cells was decreased following STZ pretreatment and/or IR/IGF1R antagonism. Using Western blot, we examined tumor grafts for IR/IGF1R expression and activity. We also determined proteins that were downstream to IR/IGF1R and responsible for signal transduction, glycolysis, angiogenesis, and apoptosis. We demonstrated that STZ-induced decrease in intra-pancreatic insulin reduced IR/IGF1R expression and activity, decreased the proteins that promoted cell survival, and increased the proteins that promoted apoptosis. These suggest that intra-pancreatic insulin supported local cancer cells. When tumor carriers were treated with PGG or EGCG, the results were similar to those seen following STZ pretreatment. Thus, the biggest changes in examined proteins were usually seen when STZ pretreatment and PGG/EGCG treatment concurred. This suggests that intra-pancreatic insulin normally combated pharmacologic effects of PGG and EGCG. In conclusion, intra-pancreatic insulin nourishes pancreatic cancer cells and helps the cells resist IR/IGF1R antagonism.
Keywords: Athymic Mice; Intra-Pancreatic Insulin; Pancreatic Cancer; Streptozotocin; The Insulin Receptor.
Similar articles
-
β-Pentagalloyl-Glucose Sabotages Pancreatic Cancer Cells and Ameliorates Cachexia in Tumor-Bearing Mice.Am J Chin Med. 2019;47(3):675-689. doi: 10.1142/S0192415X19500356. Epub 2019 Apr 9. Am J Chin Med. 2019. PMID: 30966770
-
Epigallocatechin-3-Gallate Decreases Hypoxia-Inducible Factor-1 in Pancreatic Cancer Cells.Am J Chin Med. 2023;51(3):761-777. doi: 10.1142/S0192415X23500362. Epub 2023 Mar 3. Am J Chin Med. 2023. PMID: 36867109
-
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.Mol Cell Biochem. 2013 Jan;372(1-2):83-94. doi: 10.1007/s11010-012-1448-y. Epub 2012 Sep 13. Mol Cell Biochem. 2013. PMID: 22971992 Free PMC article.
-
Anticarcinogenic effects of (-)-epigallocatechin gallate.Prev Med. 1992 Jul;21(4):503-9. doi: 10.1016/0091-7435(92)90057-o. Prev Med. 1992. PMID: 1409491 Review.
-
Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR-IGF1R hybrid receptor modulators.RSC Med Chem. 2022 Feb 21;13(4):360-374. doi: 10.1039/d1md00300c. eCollection 2022 Apr 20. RSC Med Chem. 2022. PMID: 35647546 Free PMC article. Review.
Cited by
-
Pentagalloyl Glucose: A Review of Anticancer Properties, Molecular Targets, Mechanisms of Action, Pharmacokinetics, and Safety Profile.Molecules. 2023 Jun 19;28(12):4856. doi: 10.3390/molecules28124856. Molecules. 2023. PMID: 37375411 Free PMC article. Review.
-
Investigation of the inhibition effect of 1,2,3,4,6-pentagalloyl-β-D-glucose on gastric cancer cells based on a network pharmacology approach and experimental validation.Front Oncol. 2022 Aug 3;12:934958. doi: 10.3389/fonc.2022.934958. eCollection 2022. Front Oncol. 2022. PMID: 35992839 Free PMC article.
-
The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular.Front Cell Dev Biol. 2022 Feb 17;10:844028. doi: 10.3389/fcell.2022.844028. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35252207 Free PMC article. Review.
-
Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control.Med Sci (Basel). 2021 Jun 25;9(3):48. doi: 10.3390/medsci9030048. Med Sci (Basel). 2021. PMID: 34202040 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
